Two of U.S. biotechnology’s best-known names – rare-disease specialist Genzyme Corp., which Sanofi bought last year, and RNA-interference pioneer Alnylam Pharmaceuticals Inc. – are teaming up in an agreement announced Oct. 22 to co-develop and commercialize RNAi therapeutics for transthyretin-mediated amyloidosis (ATTR) disorders in Japan and Asia-Pacific. Alnylam gets $22.5 million upfront under the deal, along with the potential for up to $50 million in milestones and mid-teen to mid-20s% royalties on product sales.
The tie-up centers on ALN-TTR02, a Phase II RNAi therapeutic discovered and developed by Alnylam, along with ALN-TTRsc, a preclinical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?